Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy

Research output: Contribution to journalArticle

Abstract

Summary This retrospective study evaluated whether early 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after two cycles of salvage chemotherapy (PET2) could predict survival after high-dose chemotherapy (HDC). Twenty-four Hodgkin lymphoma (HL) patients were included. PET2 was negative in 58% and positive in 42% of patients. Ninety per cent of patients (9/10) with positive PET2 relapsed after HDC while all but one patient with negative PET2 maintained a complete remission. The 2-year progression-free survival was 93% vs. 10% for patients with negative and positive PET2, respectively (P <0.001). This study shows that interim PET can predict the outcome after high-dose chemotherapy in HL patients.

Original languageEnglish
Pages (from-to)369-372
Number of pages4
JournalBritish Journal of Haematology
Volume145
Issue number3
DOIs
Publication statusPublished - May 2009

Keywords

  • Haemopoietic stem cell transplantation
  • Hodgkin lymphoma
  • Positron emission tomography

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy'. Together they form a unique fingerprint.

  • Cite this